COMMUNIQUÉS West-GlobeNewswire

Celularity Announces Naveen Jain to Join Board of Directors
29/09/2026
Viome founder and CEO brings a consumer-focused vision for bringing regenerative therapies to more people and advancing proactive health FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: [...]
TOMI Environmental Solutions Targets Next Phase of Growth in the Scaling Robotaxi, Drone and Robotics Economy
29/09/2026
TOMI's iHP Platform Concept Extends Core Technology into Robotaxi Depots, Drone Fleets and Robotic Systems FREDERICK, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ [...]
J-Star Holding Co., Ltd. Chairman and CEO Jonathan Chiang to Relocate to the United States to Lead Growth Initiatives
29/09/2026
TAIPEI, Taiwan, Sept. 29, 2026 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT) ("J-Star" or the "Company"), a global manufacturer of carbon fiber and composite material products, today announced that [...]
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
29/09/2026
More than 94% of participants achieved a ≥5-point MG-ADL improvement at Week 48 42% of telitacicept-treated participants achieved minimal symptom expression (MSE) at any time over 48 weeks, increasing from 23.7% over [...]
Silexion Therapeutics Announces Exercise of Warrants
29/09/2026
Cayman Islands, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS- [...]
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
29/09/2026
LEXINGTON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a [...]
Noah Medical’s Galaxy System Enters Commercial Use in Asia with First Procedure Completed in Hong Kong
29/09/2026
SAN JOSE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Medical robotics innovator Noah Medical today announced the successful completion of its first commercial procedure in Asia using the Galaxy™ System at Prince of [...]
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
29/09/2026
NEW YORK and WALTHAM, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the [...]
Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron
29/09/2026
Topline Data from First-in-Human Pharmacokinetic Study Anticipated in the Fourth Quarter of 2026 TEL AVIV, Israel, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a [...]
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
29/09/2026
Initiation of registrational Phase 3 study of VOQUEZNA® (vonoprazan) for as-needed (PRN) use in Non-Erosive Reflux Disease (NERD) builds on previously reported positive Phase 2 data Topline results expected in the first [...]
Apyx Medical Announces New Clinical Study Demonstrating Renuvion®’s Impact on Skin Quality
29/09/2026
Patients reported high satisfaction and visible improvements in skin elasticity, youthfulness, and radiance CLEARWATER, Fla., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or [...]
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
29/09/2026
- SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms- - The study will evaluate changes in blood- [...]
DiFusion to Define Therapeutic Biomaterials Category at NASS 2026
29/09/2026
Red Theater presentation will distinguish conventional biotolerable implants from materials deliberately engineered to influence the host response and participate in healing AUSTIN, Texas, Sept. 29, 2026 (GLOBE NEWSWIRE [...]
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
29/09/2026
New data show deepening improvement in ocular MG and sustained one-year efficacy in anti-AChR antibody-negative MG – broadening VYVGART's potential to treat all MG patients Real-world evidence from more than 1,100 U.S. [...]
Glass House Brands Announces Planned Retirement of Chief Financial Officer
29/09/2026
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated June 10, 2026, to its short form base shelf prospectus dated June 10, 2026. LONG BEACH, Calif. and [...]
Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB
29/09/2026
October 20th Meeting with the Division of Neurology Expected to Define Endpoint for Phase 3 PURCHASE, N.Y., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the Company or Cognition) (NASDAQ: CGTX), a [...]
Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis
29/09/2026
Descartes–08 demonstrated improvement in mean change from baseline in MG-ADL following initial treatment and retreatment; mean MG-ADL reduction of 6.6 points at Month 12 following retreatment Median interval between end [...]
Optimi Health Appoints Melanie Pump to Board of Directors
29/09/2026
Seasoned finance executive brings more than 25 years of leadership experience across technology, digital infrastructure, software, fintech and emerging growth companies VANCOUVER, British Columbia, Sept. 29, 2026 (GLOBE [...]
Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer
29/09/2026
Proposed seamless design would incorporate previously FDA-cleared dose-optimization work into a single registration-intent program aligning it with Company’s capital-efficient development strategy PHILADELPHIA, Sept. 29 [...]

Pages